Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial

Labhardt, Niklaus D.; Smit, Mikaela; Petignat, Ianis; Perneger, Thomas; Marinosci, Annalisa; Ustero, Pilar; Ribeiro, Maria Pia Diniz; Ragozzino, Silvio; Nicoletti, Giovanni Jacopo; Faré, Pietro Benedetto; Andrey, Diego O.; Jacquerioz, Frederique; Lebowitz, Dan; Agoritsas, Thomas; Meyer, Benjamin; Spechbach, Hervé; Salamun, Julien; Guessous, Idris; Chappuis, François; Kaiser, Laurent; Decosterd, Laurent Arthur; Grinsztejn, Beatriz; Bernasconi, Enos; Cardoso, Sandra W.; Calmy, Alexandra; The Copep Study Team

Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial

Detalhes bibliográficos
Autor(a) principal:	Labhardt, Niklaus D.
Data de Publicação:	2021
Outros Autores:	Smit, Mikaela, Petignat, Ianis, Perneger, Thomas, Marinosci, Annalisa, Ustero, Pilar, Ribeiro, Maria Pia Diniz, Ragozzino, Silvio, Nicoletti, Giovanni Jacopo, Faré, Pietro Benedetto, Andrey, Diego O., Jacquerioz, Frederique, Lebowitz, Dan, Agoritsas, Thomas, Meyer, Benjamin, Spechbach, Hervé, Salamun, Julien, Guessous, Idris, Chappuis, François, Kaiser, Laurent, Decosterd, Laurent Arthur, Grinsztejn, Beatriz, Bernasconi, Enos, Cardoso, Sandra W., Calmy, Alexandra, The Copep Study Team
Tipo de documento:	Artigo
Idioma:	eng
Título da fonte:	Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo:	https://www.arca.fiocruz.br/handle/icict/50471
Resumo:	University of Basel. Department of Infectious Diseases and Hospital Epidemiology. Basel, Switzerland / Swiss Tropical and Public Health Institute. Department of Medicine. Basel, Switzerland / University of Basel. Basel, Switzerland.

Metadados do item

id	CRUZ_17238f66d46d0cb6ddbabf1bb8f7b51e
oai_identifier_str	oai:www.arca.fiocruz.br:icict/50471
network_acronym_str	CRUZ
network_name_str	Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str	2135
spelling	Labhardt, Niklaus D.Smit, MikaelaPetignat, IanisPerneger, ThomasMarinosci, AnnalisaUstero, PilarRibeiro, Maria Pia DinizRagozzino, SilvioNicoletti, Giovanni JacopoFaré, Pietro BenedettoAndrey, Diego O.Jacquerioz, FrederiqueLebowitz, DanAgoritsas, ThomasMeyer, BenjaminSpechbach, HervéSalamun, JulienGuessous, IdrisChappuis, FrançoisKaiser, LaurentDecosterd, Laurent ArthurGrinsztejn, BeatrizBernasconi, EnosCardoso, Sandra W.Calmy, AlexandraThe Copep Study Team2021-12-17T12:34:37Z2021-12-17T12:34:37Z2021LABHARDT, Niklaus D. et al. Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. EClinicalMedicine, v. 42, p. 1-8, 2021.2589-5370https://www.arca.fiocruz.br/handle/icict/5047110.1016/j.eclinm.2021.101188engElsevierPost-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trialinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleUniversity of Basel. Department of Infectious Diseases and Hospital Epidemiology. Basel, Switzerland / Swiss Tropical and Public Health Institute. Department of Medicine. Basel, Switzerland / University of Basel. Basel, Switzerland.Faculty of Medicine. Geneva University Hospitals. Division of Infectious Diseases. Geneva, Switzerland / University of Geneva. Faculty of Medicine. Department of Medicine. Geneva, Switzerland.Faculty of Medicine. Geneva University Hospitals. Division of Infectious Diseases. Geneva, Switzerland.Geneva University Hospitals. Division of Clinical Epidemiology. Geneva, Switzerland.Faculty of Medicine. Geneva University Hospitals. Division of Infectious Diseases. Geneva, Switzerland.Faculty of Medicine. Geneva University Hospitals. Division of Infectious Diseases. Geneva, Switzerland.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.University of Basel. Department of Infectious Diseases and Hospital Epidemiology. Basel, Switzerland.University of Basel. Department of Infectious Diseases and Hospital Epidemiology. Basel, Switzerland / Swiss Tropical and Public Health Institute. Department of Medicine. Basel, Switzerland.University of Southern Switzerland. Ospedale Regionale di Lugano and Faculty of Medicine. Division of Infectious Diseases. Lugano, Switzerland.Faculty of Medicine. Geneva University Hospitals. Division of Infectious Diseases. Geneva, Switzerland / Geneva University Hospitals. Diagnostic Department. Division of Laboratory Medicine. Geneva, Switzerland.Geneva University Hospitals. Division and Department of Primary Care. Geneva, Switzerland.Geneva University Hospitals. Infection Control Program. Geneva, Switzerland.Geneva University Hospital. Division of General Internal Medicine. Geneva, Switzerland / McMaster University. Department of Health Research Methods, Evidence, and Impact. Hamilton, Ontario, Canada.University of Geneva. Department of Pathology and Immunology. Centre for Vaccinology. Geneva, Switzerland.Geneva University Hospitals. Division and Department of Primary Care. Geneva, Switzerland.Geneva University Hospitals. Division and Department of Primary Care. Geneva, Switzerland.Geneva University Hospitals. Division and Department of Primary Care. Geneva, Switzerland.Geneva University Hospitals. Division and Department of Primary Care. Geneva, Switzerland.Faculty of Medicine. Geneva University Hospitals. Division of Infectious Diseases. Geneva, Switzerland / Geneva University Hospitals. Geneva Centre for Emerging Viral Diseases. Geneva, Switzerland.University of Lausanne. Laboratory of Clinical Pharmacology. Lausanne, Switzerland.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.University of Southern Switzerland. Ospedale Regionale di Lugano and Faculty of Medicine. Division of Infectious Diseases. Lugano, Switzerland.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.Faculty of Medicine. Geneva University Hospitals. Division of Infectious Diseases. Geneva, Switzerland / University of Geneva. Faculty of Medicine. Department of Medicine. Geneva, Switzerland.Background: Since the beginning of the COVID-19 pandemic, no direct antiviral treatment is effective as post-exposure prophylaxis (PEP). Lopinavir/ritonavir (LPV/r) was repurposed as a potential PEP agent against COVID-19. Methods: We conducted a pragmatic open-label, parallel, cluster-randomised superiority trial in four sites in Switzerland and Brazil between March 2020 to March 2021. Clusters were randomised to receive LPV/r PEP (400/100 mg) twice daily for 5 days or no PEP (surveillance). Exposure to SARS-CoV-2 was defined as a close contact of >15 minutes in <2 metres distance or having shared a closed space for ≥2 hours with a person with confirmed SARS-CoV-2 infection. The primary outcome is the occurrence of COVID-19 defined by a SARS-CoV-2 infection (positive oropharyngeal SARS-CoV-2 PCR and/or a seroconversion) and ≥1 compatible symptom within 21 days post-enrolment. ClinicalTrials.gov (Identifier: NCT04364022); Swiss National Clinical Trial Portal: SNCTP 000003732. Findings: Of 318 participants, 157 (49.4%) were women; median age was 39 (interquartile range, 28-50) years. A total of 209 (179 clusters) participants were randomised to LPV/r PEP and 109 (95 clusters) to surveillance. Baseline characteristics were similar, with the exception of baseline SARS-CoV-2 PCR positivity, which was 3-fold more frequent in the LPV/r arm (34/209 [16.3%] vs 6/109 [5.5%], respectively). During 21-day follow-up, 48/318 (15.1%) participants developed COVID-19: 35/209 (16.7%) in the LPV/r group and 13/109 (11.9%) in the surveillance group (unadjusted hazard ratio 1.44; 95% CI, 0.76-2.73). In the primary endpoint analysis, which was adjuted for baseline imbalance, the hazard ratio for developing COVID-19 in the LPV/r group vs surveillance was 0.60 (95% CI, 0.29-1.26; p =0.18). Interpretation: The role of LPV/r as PEP for COVID-19 remains unanswered. Although LPV/r over 5 days did not significantly reduce the incidence of COVID-19 in exposed individuals, we observed a change in the directionality of the effect in favour of LPV/r after adjusting for baseline imbalance. LPV/r for this indication merits further testing against SARS-CoV-2 in clinical trials.COVID-19SARS-CoV-2LopinavirRitonavirPost-exposure prophylaxisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/50471/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALPost-exposure_Beatriz_Grinsztejn_etal_INI_2021.pdfPost-exposure_Beatriz_Grinsztejn_etal_INI_2021.pdfapplication/pdf655062https://www.arca.fiocruz.br/bitstream/icict/50471/2/Post-exposure_Beatriz_Grinsztejn_etal_INI_2021.pdf8a820d8d8d5aeea344cb4a5ddb9755b7MD52icict/504712021-12-21 12:55:58.874oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-12-21T15:55:58Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
title	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
spellingShingle	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial Labhardt, Niklaus D. COVID-19 SARS-CoV-2 Lopinavir Ritonavir Post-exposure prophylaxis
title_short	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
title_full	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
title_fullStr	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
title_full_unstemmed	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
title_sort	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
author	Labhardt, Niklaus D.
author_facet	Labhardt, Niklaus D. Smit, Mikaela Petignat, Ianis Perneger, Thomas Marinosci, Annalisa Ustero, Pilar Ribeiro, Maria Pia Diniz Ragozzino, Silvio Nicoletti, Giovanni Jacopo Faré, Pietro Benedetto Andrey, Diego O. Jacquerioz, Frederique Lebowitz, Dan Agoritsas, Thomas Meyer, Benjamin Spechbach, Hervé Salamun, Julien Guessous, Idris Chappuis, François Kaiser, Laurent Decosterd, Laurent Arthur Grinsztejn, Beatriz Bernasconi, Enos Cardoso, Sandra W. Calmy, Alexandra The Copep Study Team
author_role	author
author2	Smit, Mikaela Petignat, Ianis Perneger, Thomas Marinosci, Annalisa Ustero, Pilar Ribeiro, Maria Pia Diniz Ragozzino, Silvio Nicoletti, Giovanni Jacopo Faré, Pietro Benedetto Andrey, Diego O. Jacquerioz, Frederique Lebowitz, Dan Agoritsas, Thomas Meyer, Benjamin Spechbach, Hervé Salamun, Julien Guessous, Idris Chappuis, François Kaiser, Laurent Decosterd, Laurent Arthur Grinsztejn, Beatriz Bernasconi, Enos Cardoso, Sandra W. Calmy, Alexandra The Copep Study Team
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author
dc.contributor.author.fl_str_mv	Labhardt, Niklaus D. Smit, Mikaela Petignat, Ianis Perneger, Thomas Marinosci, Annalisa Ustero, Pilar Ribeiro, Maria Pia Diniz Ragozzino, Silvio Nicoletti, Giovanni Jacopo Faré, Pietro Benedetto Andrey, Diego O. Jacquerioz, Frederique Lebowitz, Dan Agoritsas, Thomas Meyer, Benjamin Spechbach, Hervé Salamun, Julien Guessous, Idris Chappuis, François Kaiser, Laurent Decosterd, Laurent Arthur Grinsztejn, Beatriz Bernasconi, Enos Cardoso, Sandra W. Calmy, Alexandra The Copep Study Team
dc.subject.en.pt_BR.fl_str_mv	COVID-19 SARS-CoV-2 Lopinavir Ritonavir Post-exposure prophylaxis
topic	COVID-19 SARS-CoV-2 Lopinavir Ritonavir Post-exposure prophylaxis
description	University of Basel. Department of Infectious Diseases and Hospital Epidemiology. Basel, Switzerland / Swiss Tropical and Public Health Institute. Department of Medicine. Basel, Switzerland / University of Basel. Basel, Switzerland.
publishDate	2021
dc.date.accessioned.fl_str_mv	2021-12-17T12:34:37Z
dc.date.available.fl_str_mv	2021-12-17T12:34:37Z
dc.date.issued.fl_str_mv	2021
dc.type.status.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv	info:eu-repo/semantics/article
format	article
status_str	publishedVersion
dc.identifier.citation.fl_str_mv	LABHARDT, Niklaus D. et al. Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. EClinicalMedicine, v. 42, p. 1-8, 2021.
dc.identifier.uri.fl_str_mv	https://www.arca.fiocruz.br/handle/icict/50471
dc.identifier.issn.pt_BR.fl_str_mv	2589-5370
dc.identifier.doi.none.fl_str_mv	10.1016/j.eclinm.2021.101188
identifier_str_mv	LABHARDT, Niklaus D. et al. Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. EClinicalMedicine, v. 42, p. 1-8, 2021. 2589-5370 10.1016/j.eclinm.2021.101188
url	https://www.arca.fiocruz.br/handle/icict/50471
dc.language.iso.fl_str_mv	eng
language	eng
dc.rights.driver.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	Elsevier
publisher.none.fl_str_mv	Elsevier
dc.source.none.fl_str_mv	reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ
instname_str	Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str	FIOCRUZ
institution	FIOCRUZ
reponame_str	Repositório Institucional da FIOCRUZ (ARCA)
collection	Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv	https://www.arca.fiocruz.br/bitstream/icict/50471/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/50471/2/Post-exposure_Beatriz_Grinsztejn_etal_INI_2021.pdf
bitstream.checksum.fl_str_mv	5a560609d32a3863062d77ff32785d58 8a820d8d8d5aeea344cb4a5ddb9755b7
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5
repository.name.fl_str_mv	Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv	repositorio.arca@fiocruz.br
_version_	1813009124601888768

Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial

Registros relacionados